Ligand-Stimulated Downregulation of the Alpha Interferon Receptor: Role of Protein Kinase D2

ABSTRACT Alpha interferon (IFN-α) controls homeostasis of hematopoietic stem cells, regulates antiviral resistance, inhibits angiogenesis, and suppresses tumor growth. This cytokine is often used to treat cancers and chronic viral infections. The extent of cellular responses to IFN-α is limited by the IFN-induced ubiquitination and degradation of the IFN-α/β receptor chain 1 (IFNAR1) chain of the cognate receptor. IFNAR1 ubiquitination is facilitated by the βTrcp E3 ubiquitin ligase that is recruited to IFNAR1 upon its degron phosphorylation, which is induced by the ligand. Here we report identification of protein kinase D2 (PKD2) as a kinase that mediates the ligand-inducible phosphorylation of IFNAR1 degron and enables binding of βTrcp to the receptor. Treatment of cells with IFN-α induces catalytic activity of PKD2 and stimulates its interaction with IFNAR1. Expression and kinase activity of PKD2 are required for the ligand-inducible stimulation of IFNAR1 ubiquitination and endocytosis and for accelerated proteolytic turnover of IFNAR1. Furthermore, inhibition or knockdown of PKD2 robustly augments intracellular signaling induced by IFN-α and increases the efficacy of its antiviral effects. The mechanisms of the ligand-inducible elimination of IFNAR1 are discussed, along with the potential medical significance of this regulation.

[1]  S. Fuchs,et al.  Ubiquitination-dependent regulation of signaling receptors in cancer. , 2010, Genes & cancer.

[2]  D. Baker,et al.  Inducible Priming Phosphorylation Promotes Ligand-independent Degradation of the IFNAR1 Chain of Type I Interferon Receptor* , 2009, The Journal of Biological Chemistry.

[3]  K. Mclaughlin,et al.  Mammalian Casein Kinase 1α and Its Leishmanial Ortholog Regulate Stability of IFNAR1 and Type I Interferon Signaling , 2009, Molecular and Cellular Biology.

[4]  Andreas Trumpp,et al.  IFNα activates dormant haematopoietic stem cells in vivo , 2009, Nature.

[5]  M. Jaggi,et al.  Protein kinase D1-mediated phosphorylation and subcellular localization of beta-catenin. , 2009, Cancer research.

[6]  S. Steinberg,et al.  Protein Kinase D1 Autophosphorylation via Distinct Mechanisms at Ser744/Ser748 and Ser916* , 2009, Journal of Biological Chemistry.

[7]  R. Hamanaka,et al.  Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor. , 2009, Cell host & microbe.

[8]  P. Wipf,et al.  Potent and Selective Disruption of Protein Kinase D Functionality by a Benzoxoloazepinolone* , 2008, Journal of Biological Chemistry.

[9]  Guy Pratt,et al.  A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia , 2008, Nature Genetics.

[10]  D. Baker,et al.  Ligand-independent pathway that controls stability of interferon alpha receptor. , 2008, Biochemical and biophysical research communications.

[11]  V. Malhotra,et al.  Dimeric PKD regulates membrane fission to form transport carriers at the TGN , 2007, The Journal of cell biology.

[12]  G. Lukács,et al.  Site-specific ubiquitination exposes a linear motif to promote interferon-α receptor endocytosis , 2007, The Journal of cell biology.

[13]  Lai Wei,et al.  Non‐conventional signal transduction by type 1 interferons: The NF‐κB pathway , 2007 .

[14]  Jianguo Wu,et al.  NS3 protein of hepatitis C virus regulates cyclooxygenase-2 expression through multiple signaling pathways , 2007, Virology.

[15]  J. Whitelegge,et al.  Identification of a novel phosphorylation site in c-jun directly targeted in vitro by protein kinase D. , 2007, Biochemical and biophysical research communications.

[16]  K. Hinchliffe,et al.  Regulation of type II PIP kinase by PKD phosphorylation. , 2006, Cellular signalling.

[17]  S. Fuchs,et al.  TYK2 activity promotes ligand-induced IFNAR1 proteolysis. , 2006, The Biochemical journal.

[18]  Q. Wang.  PKD at the crossroads of DAG and PKC signaling. , 2006, Trends in pharmacological sciences.

[19]  S. Pellegrini,et al.  Negative regulation of type I interferon signaling: facts and mechanisms. , 2006, Cellular and molecular biology.

[20]  L. Platanias.  Mechanisms of type-I- and type-II-interferon-mediated signalling , 2005, Nature Reviews Immunology.

[21]  A. Toker,et al.  A Phosphorylation State-specific Antibody Recognizes Hsp27, a Novel Substrate of Protein Kinase D* , 2005, Journal of Biological Chemistry.

[22]  E. Rozengurt,et al.  Protein Kinase D Signaling* , 2005, Journal of Biological Chemistry.

[23]  P. Rao,et al.  E-cadherin phosphorylation by protein kinase D1/protein kinase C{mu} is associated with altered cellular aggregation and motility in prostate cancer. , 2005, Cancer research.

[24]  T. Seufferlein,et al.  Protein Kinase D2 Mediates Activation of Nuclear Factor κB by Bcr-Abl in Bcr-Abl+ Human Myeloid Leukemia Cells , 2004, Cancer Research.

[25]  S. Fuchs,et al.  Phosphorylation and Specific Ubiquitin Acceptor Sites Are Required for Ubiquitination and Degradation of the IFNAR1 Subunit of Type I Interferon Receptor* , 2004, Journal of Biological Chemistry.

[26]  Lewis C Cantley,et al.  A rapid method for determining protein kinase phosphorylation specificity , 2004, Nature Methods.

[27]  V. Malhotra,et al.  Protein kinase D regulates basolateral membrane protein exit from trans-Golgi network , 2004, Nature Cell Biology.

[28]  Jun Qin,et al.  SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. , 2003, Genes & development.

[29]  I Dikic,et al.  Mechanisms controlling EGF receptor endocytosis and degradation. , 2003, Biochemical Society transactions.

[30]  S. Fuchs,et al.  SCFHOS ubiquitin ligase mediates the ligand‐induced down‐regulation of the interferon‐α receptor , 2003 .

[31]  A. Toker,et al.  Tyrosine Phosphorylation of Protein Kinase D in the Pleckstrin Homology Domain Leads to Activation* , 2003, The Journal of Biological Chemistry.

[32]  Guo-Ping Zhou,et al.  Triggering the Interferon Antiviral Response Through an IKK-Related Pathway , 2003, Science.

[33]  Ivan Dikic,et al.  Negative receptor signalling. , 2003, Current opinion in cell biology.

[34]  Peter Storz,et al.  Protein kinase D mediates a stress‐induced NF‐κB activation and survival pathway , 2003, The EMBO journal.

[35]  T. Seufferlein,et al.  Mechanism of Activation of Protein Kinase D2(PKD2) by the CCKB/Gastrin Receptor* , 2002, The Journal of Biological Chemistry.

[36]  John M. Kirkwood,et al.  Cancer immunotherapy: The interferon-α experience , 2002 .

[37]  D. Aaronson,et al.  A Road Map for Those Who Don't Know JAK-STAT , 2002, Science.

[38]  C. Horvath,et al.  Selective STAT Protein Degradation Induced by Paramyxoviruses Requires both STAT1 and STAT2 but Is Independent of Alpha/Beta Interferon Signal Transduction , 2002, Journal of Virology.

[39]  E. Rozengurt,et al.  Oxidative Stress Induces Protein Kinase D Activation in Intact Cells , 2000, The Journal of Biological Chemistry.

[40]  Michele Pagano,et al.  Wnt/β-Catenin Signaling Induces the Expression and Activity of βTrCP Ubiquitin Ligase Receptor , 2000 .

[41]  D. Hilton,et al.  Negative regulators of cytokine signal transduction , 1999, Cellular and Molecular Life Sciences CMLS.

[42]  V. Malhotra,et al.  Gβγ-Mediated Regulation of Golgi Organization Is through the Direct Activation of Protein Kinase D , 1999, Cell.

[43]  Y. Xiong,et al.  HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of IκB and β-catenin , 1999, Oncogene.

[44]  D. Trono,et al.  A Third-Generation Lentivirus Vector with a Conditional Packaging System , 1998, Journal of Virology.

[45]  G. Stark,et al.  How cells respond to interferons. , 1998, Annual review of biochemistry.

[46]  E. Rozengurt,et al.  Bombesin, Vasopressin, Endothelin, Bradykinin, and Platelet-derived Growth Factor Rapidly Activate Protein Kinase D through a Protein Kinase C-dependent Signal Transduction Pathway* , 1997, Journal of Biological Chemistry.

[47]  Zhou Songyang,et al.  Determination of the Specific Substrate Sequence Motifs of Protein Kinase C Isozymes* , 1997, The Journal of Biological Chemistry.

[48]  T. Kurosaki,et al.  Protein kinase C mu (PKC mu) associates with the B cell antigen receptor complex and regulates lymphocyte signaling. , 1996, Immunity.

[49]  M. Gschwendt,et al.  Inhibition of protein kinase C μ by various inhibitors. Inhibition from protein kinase c isoenzymes , 1996 .

[50]  G. Stark,et al.  High-frequency mutagenesis of human cells and characterization of a mutant unresponsive to both alpha and gamma interferons. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Lai Wei,et al.  Non-conventional signal transduction by type 1 interferons: the NF-kappaB pathway. , 2007, Journal of cellular biochemistry.

[52]  S. Fuchs,et al.  SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. , 2003, The EMBO journal.

[53]  John Kirkwood,et al.  Cancer immunotherapy: the interferon-alpha experience. , 2002, Seminars in oncology.

[54]  O. Khan,et al.  Comparative Assessment of Immunomodulating Therapies for Relapsing-Remitting Multiple Sclerosis , 2002, CNS drugs.

[55]  G. Davis.  Current treatment for chronic hepatitis C. , 2001, Reviews in gastroenterological disorders.

[56]  T. Slaga,et al.  Wnt/beta-catenin signaling induces the expression and activity of betaTrCP ubiquitin ligase receptor. , 2000, Molecular cell.

[57]  V. Malhotra,et al.  Gbetagamma-mediated regulation of Golgi organization is through the direct activation of protein kinase D. , 1999, Cell.

[58]  L. A. Goldman,et al.  Characterization of antihuman IFNAR-1 monoclonal antibodies: epitope localization and functional analysis. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[59]  Y. Xiong,et al.  HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of IkappaB and beta-catenin. , 1999, Oncogene.

[60]  N. Reich,et al.  Interferon signal transduction , 1996, Biotherapy.

[61]  M. Gschwendt,et al.  Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. , 1996, FEBS letters.

[62]  G. Stark,et al.  A protein tyrosine kinase in the interferon alpha/beta signaling pathway. , 1992, Cell.